This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

This is the first new type of pain medication to be approved in more than 20 years It is anticipated that payers will see an up-tick in the number of requests for this new drug. Journavx will ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new pain medication Journavx in a less favorable Tier 3 coverage in two ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...

On Jan. 30, the FDA granted approval for Vertex's pain medication, Journavx. It's a non-opioid treatment for moderate to severe acute pain. For the healthcare industry, this can be a valuable ...

The manufacturer Vertex Pharmaceuticals developed Journavx or suzetrigine which are 50 milligram oral tablets. The drug is meant to treat moderate to severe acute pain in patients. Acute pains come ...

The medication, called Journavx, got US regulatory clearance in January. The financial success of new drugs largely depends on how they’re treated by pharmacy benefit managers that determine ...